Abstract:The combination of immune checkpoint inhibitors and immunogenic cell death (ICD) inducers has become a promising strategy for the treatment of various cancers. However, its efficacy remains unmet because of the dense stroma and defective vasculatures in the tumor microenvironment (TME) that restricts the intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Herein, cancer-associated fibroblasts (CAFs)-targeted nanoemulsions are tailored to combine the ICD induction and the TME reprogramming to sensitize checkpoint blockade immunotherapy. Melittin, as an ICD inducer and an antifibrotic agent, is efficiently encapsulated into the nanoemulsion accompanied by a nitric oxide donor to improve its bioavailability and tumor targeting. The nanoemulsions exhibited dual functionality by directly inducing direct cancer cell death and enhancing the tumoral immunogenicity, while also synergistically reprogramming the TME through reversing the activated CAFs, decreasing collagen deposition and restoring tumor vessels. Consequently, these nanemulsions successfully facilitated the CTLs infiltration and suppressing the recruitment of immunosuppressive cells. A combination of AE-MGNPs and anti-CTLA-4 antibody greatly elicited a striking level of antitumor T-cell response to suppress tumor growth in CAFs-rich colorectal tumor models. Our work emphasized the integration of the ICD induction with simultaneous modulation of the TME to enhance the sensitivity of patients to checkpoint blockade immunotherapy.

What problem does this paper attempt to address?

The main issue this paper attempts to address is improving the efficacy of immune checkpoint inhibitors (such as anti-CTLA-4 antibodies) in cancer treatment. Specifically, the authors propose a novel nanoemulsion (AE-MGNPs) strategy to tackle the immunosuppressive characteristics of the tumor microenvironment (TME). This strategy combines immunogenic cell death (ICD) induction and TME remodeling to enhance the effectiveness of immune checkpoint blockade therapy. ### Main Issues: 1. **Limited efficacy of immune checkpoint inhibitors**: Although immune checkpoint inhibitors have shown significant effects in certain types of cancer, their overall efficacy remains limited, especially in tumors lacking pre-existing T cells. 2. **Immunosuppressive tumor microenvironment (TME)**: The dense stroma and defective vascular structure in the TME limit the infiltration of cytotoxic T lymphocytes (CTLs), further hindering the effectiveness of immunotherapy. 3. **Role of cancer-associated fibroblasts (CAFs)**: CAFs shape an immunosuppressive TME by producing dense extracellular matrix (ECM) and secreting inhibitory cytokines, which impede T cell accumulation. ### Solution: - **Design and preparation of nanoemulsion**: The authors designed a nanoemulsion (AE-MGNPs) containing melittin (a bee venom peptide) and a nitric oxide donor (GSNO). These components can induce immunogenic cell death and remodel the TME, respectively. - **ICD induction**: Melittin acts as an ICD inducer, directly killing cancer cells and enhancing tumor immunogenicity. - **TME remodeling**: GSNO, as a nitric oxide donor, can improve tumor vascular function, reduce ECM deposition, and reverse activated CAFs, thereby reducing immunosuppression. - **Combination therapy**: Combining AE-MGNPs with anti-CTLA-4 antibodies significantly enhances anti-tumor T cell responses and inhibits tumor growth in a CAF-rich colorectal tumor model. ### Experimental Results: - **In vitro experiments**: AE-MGNPs exhibit selective cytotoxicity towards cancer cells without affecting CAFs and vascular endothelial cells. Additionally, AE-MGNPs effectively induce immunogenic cell death, as evidenced by high expression of calreticulin (CRT) on the cell surface. - **In vivo experiments**: In a mouse colorectal tumor model, AE-MGNPs combined with anti-CTLA-4 antibody treatment significantly inhibited tumor growth, increased T cell infiltration, and reduced the recruitment of immunosuppressive cells. ### Conclusion: This study successfully enhances the efficacy of immune checkpoint blockade therapy by combining ICD induction and TME remodeling, providing new insights and methods for future cancer immunotherapy.

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Strengthening the Combinational Immunotherapy from Modulating the Tumor Inflammatory Environment via Hypoxia-Responsive Nanogels

Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models

Synergistic immunotherapy with a calcium-based nanoinducer: evoking pyroptosis and remodeling tumor-associated macrophages for enhanced antitumor immune response

Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors

Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Cancer cell membrane–encapsulated biomimetic nanoparticles for tumor immuno-photothermal therapy

Combination Cancer Immunotherapy Of Nanoparticle-Based Immunogenic Cell Death Inducers And Immune Checkpoint Inhibitors

Tumor Microenvironment‐Specific Driven Nanoagents for Synergistic Mitochondria Damage‐Related Immunogenic Cell Death and Alleviated Immunosuppression

Synergistic Reinforcing of Immunogenic Cell Death and Transforming Tumor‐Associated Macrophages Via a Multifunctional Cascade Bioreactor for Optimizing Cancer Immunotherapy

Stepwise Targeting and Tandem Responsive Peptide Nanoparticles Enhance Immunotherapy through Prolonged Drug Retention

CaCO3-complexed pH-responsive nanoparticles encapsulating mitoxantrone and celastrol enhance tumor chemoimmunotherapy

Combination of Cryo‐Shocked M1 Macrophages and Lonidamine Nanodrugs Enables Potent Chemo‐Immunotherapy

Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy

Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death

CaCO 3 -complexed pH-responsive nanoparticles encapsulating mitoxantrone and celastrol enhance tumor chemoimmunotherapy